Glucagon Like Peptide-1 Agonists Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Size, Share & Trends, Drivers, Restraints, Opportunities, Manufacturer, Applications, And Segments

  • AMR-1064425
  • May 2021
  • Pharmaceuticals
  • 126 Pages
The Glucagon Like Peptide-1 Agonists market research report provides an in-depth analysis of the currents trends, latest developments, scenario, market size, various drivers, restraints, and major players along with their profile details. Research report offers the historic data for year 2018 and 2019 and also provides the forecast data from year 2020 to 2028 which is based on revenue (USD Million). With the help of all these information research report helps the market participants to improve market positions. With the help of all these insights Glucagon Like Peptide-1 Agonists market research report recommends a business strategy for present market participants to strengthen their position in the market.
 
Report Parameters Details of Parameter
Market Size xx Million
Based Year 2020
Forecast Period Covered 2020 – 2028
Units for value Revenue in USD million and CAGR from 2020 to 2028
Covered Segments Component, Types, Applications, End-Users, and more.
Companies Covered NovoNordisk, Sanofi, Eli Lilly, AstraZeneca
Region Covered North America, Europe, Asia Pacific, Latin America, Middle East and Africa

COVID-19 Impact Analysis
The analysis of covid-19 is based on the impact of the current pandemic situation on market scenarios. This includes impact of covid-19 outbreak on overall revenue, market segments as well as regional market. The report also puts light on detailed impact analysis by taking into consideration all the government policies imposed during the pandemic situation, temporary shutdown of manufacturing units, current state of supply chain and distributors, and its future impacts on the growth of overall market. The market study will assist user to understand the global demand and impose strategic business plans to compete with the peers.

Furthermore, the research report includes the detailed information about major players and provides the data regarding the current market scenario as well as upcoming market opportunities or challenges. Similarly, in segment report covers the types, and applications according to the countries and key regions. The research report consists the various drivers and restraints for Glucagon Like Peptide-1 Agonists market along with their effects over the forecast period. Similarly, according to the region Glucagon Like Peptide-1 Agonists market research report includes the study of opportunities available in the market situation.

The Glucagon Like Peptide-1 Agonists market research report provides the in-depth data analysis by using the various graphs, figures, charts, and tables. Furthermore, the report provides the different business challenges which are impacting market growth in all direction.

Major Key Players for Global Glucagon Like Peptide-1 Agonists Market:
The Glucagon Like Peptide-1 Agonists market research report offers the company profile of major key players including progress trends, competitive landscape breakdown, and key in regions development status. NovoNordisk, Sanofi, Eli Lilly, AstraZeneca

Glucagon Like Peptide-1 Agonists Market Segmentation Analysis:
By Drug
EXENATIDE
Liraglutide
Dulaglutide
Lixisenatide

Global Glucagon Like Peptide-1 Agonists Market Segmentation by Regions:
In regional analysis, Glucagon Like Peptide-1 Agonists market research report provides the detailed analysis from various regions and also contains the detailed analysis of country. Along with market revenue, market value report also offers the forecast analysis for the following countries and regions. Global Glucagon Like Peptide-1 Agonists market report covers the various geographical regions such as North America, Asia-Pacific, Europe, Latin America, and Middle East & Africa. Also, various countries included are Canada, U.K., France, the U.S., Japan, China, India, and Germany and so on.

North America Region for Glucagon Like Peptide-1 Agonists Market: Value and Forecast
  • U.S.
  • Canada
 Europe Region for Glucagon Like Peptide-1 Agonists Market: Value and Forecast
  • UK
  • Germany
  • France
  • Rest of the Europe
 Asia Pacific Region for Glucagon Like Peptide-1 Agonists Market: Value and Forecast
  • China
  • Japan
  • India
  • Rest of the Asia Pacific
 Latin America Region for Glucagon Like Peptide-1 Agonists Market: Value and Forecast
  • Mexico
  • Brazil
  • Rest of the Latin America
 Middle East and Africa for Glucagon Like Peptide-1 Agonists Market: Value and Forecast
  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa


Important Points Covered by Report:
  • To analyze the value of the Glucagon Like Peptide-1 Agonists market, according to the key region.
  • To study the Glucagon Like Peptide-1 Agonists market current trends, prospects and also their participation in the entire sector.
  • Report consists the in-depth information related to the region/countries, major key players, current trends and their analysis, product type, applications, and other background information
  • Report provides the detailed information about drivers, restraints and future scope of Glucagon Like Peptide-1 Agonists market.
  • Report covers the information about historic data analysis as well as forecast period analysis.

Global Glucagon Like Peptide-1 Agonists research report consist the information about overall sales and revenue during the historic and forecasted period of 2018 to 2028. Additionally, this report covers the inside and out factual examination and the market elements and requests which give an entire situation of the business.

Key Analytical Areas:
The report aims to offer a complete solution to various businesses operating in the Glucagon Like Peptide-1 Agonists market in making strategic decisions based on credible information and actionable insights. Thereby, the report covers various aspects of your requirements such as industry overview, market dynamics, regional analysis and competitive landscape. The report aims to provide insights to businesses in the Glucagon Like Peptide-1 Agonists market for numerous purposes such as:

    1. Strategic Decision Making:
With the help of this report, key decision makers can quickly analyze and identify growth opportunities in terms of numerous segments across various geographical regions. Thereby, this report enables organizations to identify and make strategic investments in specific market segments in order to gain maximum return on investment.

     2. Actionable Insights:
The report offers a deep dive into how companies are leveraging market conditions to make the most in the Glucagon Like Peptide-1 Agonists market. Thereby, the report offers numerous actionable insights into the best practices and key success factors relevant in the Glucagon Like Peptide-1 Agonists market. Using the insights included in the report, businesses can make quick decisions to achieve success in business operations.

     3. Competitive Snapshot:
In addition, to detailed information on the companies operating in the Glucagon Like Peptide-1 Agonists market, the report also includes a competitive snapshot of all the companies covered in the report. Thereby, this offers a visual representation of how all the companies stand comparatively based on their competencies, geographic presence, market hold, years of operations, employee and financial strength, among others.

Have query on this report?

Make an Enquiry
1. Preface
     1.1. Report Scope and Description
     1.2. Research Methodology
          1.2.1. Phase I-Secondary Research
          1.2.2. Phase II-Primary Research
          1.2.3. Phase II-Expert Panel Review
          1.2.4. Assumptions
          1.2.5. Approach Adopted

2. Executive Summarysegment Form
     2.1. Global Glucagon Like Peptide-1 Agonists Market Snapshot
          2.1.1. Global Glucagon Like Peptide-1 Agonists Market By Drug,2019
               2.1.1.1.EXENATIDE
               2.1.1.2.Liraglutide
               2.1.1.3.Dulaglutide
               2.1.1.4.Lixisenatide
          2.1.2. Global Glucagon Like Peptide-1 Agonists Market By Drug,2019
               2.1.2.1.EXENATIDE
               2.1.2.2.Liraglutide
               2.1.2.3.Dulaglutide
               2.1.2.4.Lixisenatide
          2.1.3. Global Glucagon Like Peptide-1 Agonists Market By End-use,2019
          2.1.4. Global Glucagon Like Peptide-1 Agonists Market By Geography,2019

3. Global Glucagon Like Peptide-1 Agonists Market Dynamics
     3.1. Market Overview
     3.2. Market Inclination Insights Analysis
     3.3. Drivers
     3.4. Challenges
     3.5. Future Prospects
     3.6. Impact Analysis of Drivers and Challenges During the Forecast Period, (2020-2028)

4. Global Glucagon Like Peptide-1 Agonists Market Size (US$), By Drug, 2018 – 2028 
     4.1. Overview
          4.1.1. Market Share Analysis By Drug, 2019 vs.2028
          4.1.2. Attractive Investment Proposition By Drug, 2020
     4.2. Global Glucagon Like Peptide-1 Agonists Market Size (US$), By Drug, 2018 – 2028

5. Global Glucagon Like Peptide-1 Agonists Market Size (US$), By Drug, 2018 – 2028 
     5.1. Overview
          5.1.1. Market Share Analysis By Drug, 2019 vs.2028
          5.1.2. Attractive Investment Proposition By Drug, 2020
     5.2. Global Glucagon Like Peptide-1 Agonists Market Size (US$), By Drug, 2018 – 2028

6. Global Glucagon Like Peptide-1 Agonists Market Size (US$), By End-use, 2018 – 2028 
     6.1. Overview
          6.1.1. Market Share Analysis By End-use, 2019 vs.2028
          6.1.2. Attractive Investment Proposition By End-use, 2020
     6.2. Global Glucagon Like Peptide-1 Agonists Market Size (US$), By End-use, 2018 – 2028

7. Global Glucagon Like Peptide-1 Agonists Market Size (US$), By Geography, 2018 – 2028
     7.1. Overview
          7.1.1. Market Share Analysis by Geography, 2019 vs. 2028
          7.1.2. Attractive Investment Proposition by Geography, 2020
     7.2. North America Glucagon Like Peptide-1 Agonists Market Analysis, 2018 – 2028 
          7.2.1. North America Glucagon Like Peptide-1 Agonists Market Size (US$), By Country, 2018 – 2028 
               7.2.1.1. U.S.
               7.2.1.2. Canada
          7.2.2. North America Glucagon Like Peptide-1 Agonists Market Size (US$), By Drug, 2018 – 2028
          7.2.3. North America Glucagon Like Peptide-1 Agonists Market Size (US$), By Drug, 2018 – 2028
          7.2.4. North America Glucagon Like Peptide-1 Agonists Market Size (US$), By End-use, 2018 – 2028
     7.3. Europe Glucagon Like Peptide-1 Agonists Market Analysis, 2018 – 2028 
          7.3.1.  Europe Glucagon Like Peptide-1 Agonists Market Size (US$), By Country, 2018 – 2028 
               7.3.1.1. U.K.
               7.3.1.2. Germany
               7.3.1.3. France
               7.3.1.4. Rest of Europe
          7.3.2. Europe Glucagon Like Peptide-1 Agonists Market Size (US$), By Drug, 2018 – 2028
          7.3.3. Europe Glucagon Like Peptide-1 Agonists Market Size (US$), By Drug, 2018 – 2028
          7.3.4. Europe Glucagon Like Peptide-1 Agonists Market Size (US$), By End-use, 2018 – 2028
     7.4. Asia Pacific Glucagon Like Peptide-1 Agonists Market Analysis , 2018 – 2028
          7.4.1.  Asia Pacific Glucagon Like Peptide-1 Agonists Market Size (US$), By Country, 2018 – 2028 
               7.4.1.1. China
               7.4.1.2. Japan
               7.4.1.3. India
               7.4.1.4. Rest of Asia Pacific
          7.4.2. Asia Pacific Glucagon Like Peptide-1 Agonists Market Size (US$), By Drug, 2018 – 2028
          7.4.3. Asia Pacific Glucagon Like Peptide-1 Agonists Market Size (US$), By Drug, 2018 – 2028
          7.4.4. Asia Pacific Glucagon Like Peptide-1 Agonists Market Size (US$), By End-use, 2018 – 2028
     7.5. Latin America Glucagon Like Peptide-1 Agonists Market Analysis, 2018 – 2028 
          7.5.1.  Latin America Glucagon Like Peptide-1 Agonists Market Size (US$), By Country, 2018 – 2028 
               7.5.1.1. Brazil
               7.5.1.2. Mexico
               7.5.1.3. Rest of Latin America
          7.5.2. Latin America Glucagon Like Peptide-1 Agonists Market Size (US$), By Drug, 2018 – 2028
          7.5.3. Latin America Glucagon Like Peptide-1 Agonists Market Size (US$), By Drug, 2018 – 2028
          7.5.4. Latin America Glucagon Like Peptide-1 Agonists Market Size (US$), By End-use, 2018 – 2028
     7.6. Middle East & Africa (MEA) Glucagon Like Peptide-1 Agonists Market Analysis, 2018 – 2028 
          7.6.1.  MEA Glucagon Like Peptide-1 Agonists Market Size (US$), By Region, 2018 – 2028 
               7.6.1.1. GCC Countries
               7.6.1.2. South Africa
               7.6.1.3. Rest of MEA
          7.6.2. MEA Glucagon Like Peptide-1 Agonists Market Size (US$), By Drug, 2018 – 2028
          7.6.3. MEA Glucagon Like Peptide-1 Agonists Market Size (US$), By Drug, 2018 – 2028
          7.6.4. MEA Glucagon Like Peptide-1 Agonists Market Size (US$), By End-use, 2018 – 2028

8. Company Profiles
     8.1. Competitive Analysis 
     8.2. Market Positioning of Key Vendors 
     8.3. Key Strategies adopted by the Leading Players
     8.4. Key Glucagon Like Peptide-1 Agonists Providers
        8.4.1 NovoNordisk
                8.4.1.1 Business Description
                8.4.1.2 NovoNordisk Geographic Operations
                8.4.1.3 NovoNordisk Financial Information
                8.4.1.4 NovoNordisk Product Positions/Portfolio
                8.4.1.5 NovoNordisk Key Developments
        8.4.2 Sanofi
                8.4.2.1 Business Description
                8.4.2.2 Sanofi Geographic Operations
                8.4.2.3 Sanofi Financial Information
                8.4.2.4 Sanofi Product Positions/Portfolio
                8.4.2.5 Sanofi Key Developments
        8.4.3 Eli Lilly
                8.4.3.1 Business Description
                8.4.3.2 Eli Lilly Geographic Operations
                8.4.3.3 Eli Lilly Financial Information
                8.4.3.4 Eli Lilly Product Positions/Portfolio
                8.4.3.5 Eli Lilly Key Developments
        8.4.4 AstraZeneca
                8.4.4.1 Business Description
                8.4.4.2 AstraZeneca Geographic Operations
                8.4.4.3 AstraZeneca Financial Information
                8.4.4.4 AstraZeneca Product Positions/Portfolio
                8.4.4.5 AstraZeneca Key Developments

LIST OF TABLES

TABLE 1 Market Snapshot: Global Glucagon Like Peptide-1 Agonists Market 
TABLE 2 Impact Indicators 
TABLE 3 Impact Analysis of Drivers and Restraints 
TABLE 4 North America Glucagon Like Peptide-1 Agonists Market Revenue, By Drug, 2018 – 2028 (US$ Mn) 
TABLE 5 North America Glucagon Like Peptide-1 Agonists Market Revenue, By Drug, 2018 – 2028 (US$ Mn) 
TABLE 6 North America Glucagon Like Peptide-1 Agonists Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 7 Europe Glucagon Like Peptide-1 Agonists Market Revenue, By Drug, 2018 – 2028 (US$ Mn) 
TABLE 8 Europe Glucagon Like Peptide-1 Agonists Market Revenue, By Drug, 2018 – 2028 (US$ Mn) 
TABLE 9 Europe Glucagon Like Peptide-1 Agonists Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 10 Asia Pacific Glucagon Like Peptide-1 Agonists Market Revenue, By Drug, 2018 – 2028 (US$ Mn) 
TABLE 11 Asia Pacific Glucagon Like Peptide-1 Agonists Market Revenue, By Drug, 2018 – 2028 (US$ Mn) 
TABLE 12 Asia Pacific Glucagon Like Peptide-1 Agonists Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 13 Latin America Glucagon Like Peptide-1 Agonists Market Revenue, By Drug, 2018 – 2028 (US$ Mn) 
TABLE 14 Latin America Glucagon Like Peptide-1 Agonists Market Revenue, By Drug, 2018 – 2028 (US$ Mn) 
TABLE 15 Latin America Glucagon Like Peptide-1 Agonists Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 16 MEA Glucagon Like Peptide-1 Agonists Market Revenue, By Drug, 2018 – 2028 (US$ Mn) 
TABLE 17 MEA Glucagon Like Peptide-1 Agonists Market Revenue, By Drug, 2018 – 2028 (US$ Mn) 
TABLE 18 MEA Glucagon Like Peptide-1 Agonists Market Revenue, By End-use, 2018 – 2028 (US$ Mn)

LIST OF FIGURES

FIG. 1 Global Glucagon Like Peptide-1 Agonists: Market Segmentation 
FIG. 2 Global Glucagon Like Peptide-1 Agonists Market: Research Methodology 
FIG. 3 Top-Down and Bottom-up Approach 
FIG. 4 Global Glucagon Like Peptide-1 Agonists Market, By Drug, 2019 (US$ Mn) 
FIG. 5 Global Glucagon Like Peptide-1 Agonists Market, By Drug, 2019 (US$ Mn) 
FIG. 6 Global Glucagon Like Peptide-1 Agonists Market, By End-use, 2019 (US$ Mn) 
FIG. 7 Global Glucagon Like Peptide-1 Agonists Market, By Geography, 2019 (US$ Mn) 
FIG. 8 Global Glucagon Like Peptide-1 Agonists Market Revenue and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG. 9 Attractive Investment Proposition 
FIG. 10 Market Positioning of Key Glucagon Like Peptide-1 Agonists Providers, 2019
FIG. 11 Global Glucagon Like Peptide-1 Agonists Market Revenue Contribution, By Drug, 2019 & 2028 (Value %) 
FIG. 12 Global Glucagon Like Peptide-1 Agonists Market Revenue Contribution, By Drug, 2019 & 2028 (Value %) 
FIG. 13 Global Glucagon Like Peptide-1 Agonists Market Revenue Contribution, By End-use, 2019 & 2028 (Value %) 
FIG. 14 North America Glucagon Like Peptide-1 Agonists Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 15 Europe Glucagon Like Peptide-1 Agonists Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 16 Asia Pacific Glucagon Like Peptide-1 Agonists Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 17 Latin America Glucagon Like Peptide-1 Agonists Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 18 MEA Glucagon Like Peptide-1 Agonists Market Revenue, 2018 – 2028, (US$ Mn)

Key Takeaways:

1. Market value and estimate of the Glucagon Like Peptide-1 Agonists market for the period from 2020 to 2028
2. Compounded annual growth rate (CAGR%) for individual segments in various regional markets for a period from 2020 to 2028
3. Value chain analysis
4. Market share study combined with competitive landscape of major players
5. Profiles of major market players covering overall business operations, geographic occurrence, product portfolio, financial status and news coverage 

List of Tables

TABLE  Market Snapshot: Global Glucagon Like Peptide-1 Agonists Market
TABLE  Impact Pointers
TABLE  Impact Analysis of Drivers and Restraints
TABLE  North America Glucagon Like Peptide-1 Agonists Market Value, By Segment1, 2018 – 2028
TABLE  North America Glucagon Like Peptide-1 Agonists Market Value, By Segment2, 2018 – 2028
TABLE  North America Glucagon Like Peptide-1 Agonists Market Value, By Country, 2018 – 2028
TABLE  Europe Glucagon Like Peptide-1 Agonists Market Value, By Segment1, 2018 – 2028
TABLE  Europe Glucagon Like Peptide-1 Agonists Market Value, By Segment2, 2018 – 2028
TABLE  Europe Glucagon Like Peptide-1 Agonists Market Value, By Country, 2018 – 2028
TABLE  Asia Pacific Glucagon Like Peptide-1 Agonists Market Value, By Segment1, 2018 – 2028
TABLE  Asia Pacific Glucagon Like Peptide-1 Agonists Market Value, By Segment2, 2018 – 2028
TABLE  Asia Pacific Glucagon Like Peptide-1 Agonists Market Value, By Country, 2018 – 2028
TABLE  Latin America Glucagon Like Peptide-1 Agonists Market Value, By Segment1, 2018 – 2028
TABLE  Latin America Glucagon Like Peptide-1 Agonists Market Value, By Segment2, 2018 – 2028
TABLE  Latin America Glucagon Like Peptide-1 Agonists Market Value, By Country, 2018 – 2028
TABLE  MEA Glucagon Like Peptide-1 Agonists Market Value, By Segment1, 2018 – 2028
TABLE  MEA Glucagon Like Peptide-1 Agonists Market Value, By Segment2, 2018 – 2028
TABLE  MEA Glucagon Like Peptide-1 Agonists Market Value, By Country, 2018 – 2028
TABLE  NovoNordisk: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Sanofi: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Eli Lilly: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  AstraZeneca: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
 

List of Figures

FIG.  Global Glucagon Like Peptide-1 Agonists Market: Research Methodology
FIG.  Top-Down and Bottom Up Approach
FIG.  Global Glucagon Like Peptide-1 Agonists Market, By Segment1, 2019 (US$ Mn)
FIG.  Global Glucagon Like Peptide-1 Agonists Market, By Segment2, 2019 (US$ Mn)
FIG.  Global Glucagon Like Peptide-1 Agonists Market, By Geography, 2019 (US$ Mn)
FIG.  Global Glucagon Like Peptide-1 Agonists Market Value and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG.  Attractive Investment Proposition
FIG.  Market Positioning of Key Glucagon Like Peptide-1 Agonists Providers, 2016
FIG.  Global Glucagon Like Peptide-1 Agonists Market Value Share, By Segment1, 2019 & 2028 (% Value)
FIG.  Global Liraglutide Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Dulaglutide Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Lixisenatide Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Glucagon Like Peptide-1 Agonists Market Value Share, By Segment2, 2019 & 2028 (% Value)
FIG.  Global Liraglutide Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Dulaglutide Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Lixisenatide Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Market Value, 2018 – 2028, (US$ Mn)
FIG.  U.S. Glucagon Like Peptide-1 Agonists Market Value, 2018 – 2028, (US$ Mn)
FIG.  Canada Glucagon Like Peptide-1 Agonists Market Value, 2018 – 2028, (US$ Mn)
FIG.  UK Glucagon Like Peptide-1 Agonists Market Value, 2018 – 2028, (US$ Mn)
FIG.  Germany Glucagon Like Peptide-1 Agonists Market Value, 2018 – 2028, (US$ Mn)
FIG.  France Glucagon Like Peptide-1 Agonists Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Europe Glucagon Like Peptide-1 Agonists Market Value, 2018 – 2028, (US$ Mn)
FIG.  China Glucagon Like Peptide-1 Agonists Market Value, 2018 – 2028, (US$ Mn)
FIG.  Japan Glucagon Like Peptide-1 Agonists Market Value, 2018 – 2028, (US$ Mn)
FIG.  India Glucagon Like Peptide-1 Agonists Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Asia Pacific Glucagon Like Peptide-1 Agonists Market Value, 2018 – 2028, (US$ Mn)
FIG.  Mexico Glucagon Like Peptide-1 Agonists Market Value, 2018 – 2028, (US$ Mn)
FIG.  Brazil Glucagon Like Peptide-1 Agonists Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Latin America Glucagon Like Peptide-1 Agonists Market Value, 2018 – 2028, (US$ Mn)
FIG.  GCC Countries Glucagon Like Peptide-1 Agonists Market Value, 2018 – 2028, (US$ Mn)
FIG.  South Africa Glucagon Like Peptide-1 Agonists Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of MEA Glucagon Like Peptide-1 Agonists Market Value, 2018 – 2028, (US$ Mn)